Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- CheckyesterdayChange DetectedThe notice about government funding and potential delays was removed from the page. This banner previously informed users about data reliability and operating status.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe Record History page now shows additional recent versions with updated submission dates and status notes. The version history appears longer, reflecting ongoing updates to the study record.SummaryDifference0.1%

- Check37 days agoChange DetectedAdds current date (2025-10-10) and a new study status entry (2025-09-30), while removing an older date (2025-06-13. Overall, updates to time-sensitive content and status tracking.SummaryDifference0.8%

- Check44 days agoChange DetectedSummary: The page now displays a government-operating-status notice and announces a software version upgrade to v3.2.0, replacing the old v3.1.0.SummaryDifference9%

- Check51 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.2%

- Check65 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing Revision: v3.0.1, and the Back to Top element has been removed. This reflects a simple version bump and a minor UI tweak with no changes to core content or key data.SummaryDifference0.6%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.